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osting by EAbstract In the few reported cases of prosthetic mitral valve thrombosis, where surgical interven-
tion was considered as high risk, ﬁbrinolytic therapy had proved life saving. The authors present clin-
ical, laboratory, and imaging data from such a patient, with prosthetic mitral valve thrombosis and
its successful management with tenecteplase. The use of tenecteplase as a viable ﬁbrinolytic agent for
the ﬁrst time was justiﬁed, due to the lack of immunogenicity concerns compared to streptokinase.
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Prosthetic valve thrombosis (PVT) is considered a serious com-
plication following a native cardiac valve replacement. More
common with metallic prosthesis, it may result in disabling
peripheral thromboembolism and life-threatening deteriora-
tion in a patient’s clinical status unless dealt with appropriately
and promptly. We report our ﬁrst experience with tenecteplaseardiac Science Department,
900, Abu Dhabi, United Arab
971 26104477.
(M. Ayyub Ghori).
y. Production and hosting by
Saud University.
lsevierused to treat a critically ill patient, diagnosed with mitral PVT
with cardiac decompensation.2. Case report
A 72-year-old woman presented to our emergency room with
complaint of progressively worsening shortness of breath
(NYHA functional class III–IV) for one day. A prosthetic
valve had been inserted in the mitral position four years ago.
The patient was on a maintenance dose of warfarin, except
for the past week. On physical examination, she exhibited
frank pulmonary edema and mufﬂed ﬁrst heart sounds. The
international normalized ratio (INR) was sub-therapeutic at
1.1 (target range is 2.5–3.5). Transthoracic echocardiogram
showed a mass attached to the prosthetic mitral valve and a
trans-valvular peak and mean gradient of 58 and 35 mm Hg,
respectively (Fig. 1). Fluoroscopic examination conﬁrmed that
one of the leaﬂets was stuck in the closed position and the
other had restricted movement. The patient being high risk
for surgery, a bolus of 40 mg of tenecteplase was given intrave-
nously. A few hours later, the patient had marked alleviation
Figure 1 Continuous wave Doppler study showing a markedly
elevated gradient across the prosthetic mitral valve before
tenecteplase.
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lic ﬁrst heart sound. The trans-prosthetic peak and mean gra-
dients improved signiﬁcantly to 10 and 4 mm Hg, respectively (
Fig. 2). Fluoroscopic examination conﬁrmed normal move-
ment of the prosthesis. There was no evidence of embolic com-
plications or bleeding. The patient was discharged after
attaining the recommended level of anticoagulation.
3. Discussion
A number of factors can contribute to thrombotic dysfunction
of a prosthetic heart valve and inadequate anticoagulation can
play a major role in this. In the current case, the INR was 1.1.
Flow and pressure dynamics of different cardiac chambers and
hemodynamic proﬁle of a prosthetic valve are the other con-
siderable factors. Pannus in-growth, restricting the prosthetic
valve movement, should also be considered, because ﬁbrino-Figure 2 Continuous wave Doppler study showing a signiﬁcant
drop in the pressure gradient across the prosthetic mitral valve
after tenecteplase.lytic therapy will be ineffective. Duration of symptoms, antico-
agulation status, and qualitative and quantitative ultrasound
intensity of the mass obstructing the valve may help differenti-
ate pannus from thrombus (Barbetseas and Nagueh, 1998).
Our patient’s symptoms were of recent onset and the INR
was not within the desired range.
Patients with a stuck artiﬁcial valve present with different
signs and symptoms, depending on location and degree of
obstruction. When this condition involves mitral prosthesis,
such as in this case, patients usually complain of shortness of
breath and have signs of heart failure. In some cases, the ﬁrst
presentation may be a systemic thromboembolic event.
Transthoracic echocardiography and ﬂuoroscopy are two
important diagnostic tools for patients with suspicion of
PVT. Their concomitant use makes a correct diagnosis of
PVT in 85% of patients with suspected valve obstruction. Sen-
sitivity, speciﬁcity, and positive predictive value are 87%, 78%,
80%, and 75%, 64%, 57% for ﬂuoroscopy and transthoracic
echocardiography, respectively (Montorsi et al., 2000). In this
case, we used the two techniques to make the diagnosis and to
assess the response to the treatment.
Since no randomized controlled trial has been conducted
comparing medical to surgical therapy for PVT, optimal treat-
ment remains controversial. According to the American Col-
lege of Cardiology/American Heart Association guidelines
(ACC/AHA) (Smith, 2008), emergency surgery is reasonable
for a thrombosed left-sided prosthetic valve and NYHA func-
tional class III–IV symptoms (Class IIa, Level of Evidence: C)
while ﬁbrinolytic therapy may be considered as a ﬁrst-line ther-
apy for patients with a thrombosed left-sided prosthetic valve,
NYHA functional class III–IV symptoms, and a small or a
large clot burden (Class IIb, Level of Evidence: B and C,
respectively), if surgery is high risk or not available. Further-
more, thrombolysis therapy as ﬁrst choice in prosthetic heart
valve thrombosis has been supported in the current literature
(Ca´ceres-Lo´riga et al., 2006).
Considering our patient’s high risk for emergency surgery
(elderly, fragile lady with severe respiratory distress, marked
tachycardia and NYHA Class IV heart failure), we opted for
ﬁbrinolytic strategy using tenecteplase. This agent has been
used in patients with aortic PVT (Maegdefessel et al., 2008)
and can act as a viable alternative to streptokinase (Bozug˘an
et al., 2001), for which immunogenicity issues can arise. The
patient made an excellent recovery from her symptoms. Fol-
low-up cardiac ultrasound and ﬂuoroscopic examination con-
ﬁrmed the resolution of the thrombus, restoration of the
prosthetic leaﬂets mobility and a signiﬁcant improvement of
trans-prosthetic Doppler parameters. There was no thrombo-
embolic or hemorrhagic complication and the patient was dis-
charged on warfarin, after achieving the desired INR.
This case afﬁrms the use of ﬁbrinolytic agent as a ﬁrst-line
therapy in high risk patients with mitral PVT and severe heart
failure, matching ACC/AHA guidelines. Because of its
remarkable response in this case, tenecteplase may be consid-
ered as a useful ﬁbrinolytic agent in cases of mitral PVT.References
Barbetseas, J., Nagueh, S.F., 1998. Differentiating thrombus from
pannus formation in obstructed mechanical prosthetic valves: an
evaluation of clinical, transthoracic and transesophageal echocar-
diographic parameters. J. Am. Coll. Cardiol. 32, 1410–1417.
Tenecteplase in prosthetic mitral valve thrombosis 95Bozug˘an, N., Erdog˘an, H.B., Keles, C., et al., 2001. Recurrent
obstructive mechanical valve thrombosis in mitral position. Int. J.
Cardiol. 2, 197–198.
Ca´ceres-Lo´riga, F.M., Pe´rez-Lo´pez, H., Morlans-Herna´ndez, K.,
et al., 2006. Thrombolysis as ﬁrst choice therapy in prosthetic
heart valve thrombosis. A study of 68 patients. J. Thromb.
Thrombolysis 21 (2), 185–190.
Maegdefessel, L., Issa, H., Scheler, C., et al., 2008. 27-Year old
pregnant woman with syncope and dyspnea after aortic alloplastic
heart valve replacement 15 years ago. Internist 49 (7), 868–872.Montorsi, P., De Bernardi, F., Muratori, M., et al., 2000. Role of cine-
ﬂuoroscopy, transthoracic, and transesophageal echocardiography
in patients with suspected prosthetic heart valve thrombosis. Am. J.
Cardiol. 85, 58–64.
Smith Jr., S.C., 2008. Focused update incorporated into the ACC/
AHA 2006 guidelines for the management of patients with valvular
heart disease: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines.
Circulation 118, e523–e661.
